scholarly journals Synthesis of Silver Nano-Particles from Natural Products and its Applications

2019 ◽  
Vol 18 (2) ◽  
pp. 37-44
Author(s):  
Anjali Sharma ◽  
Sherin Thomas ◽  
Agnes Mary Mathew ◽  
Anil Kumar Agarwal
Keyword(s):  
Silver Nanoparticles ◽  
Natural Products ◽  
Drug Discovery ◽  
Nano Particles ◽  
Multiple Drug ◽  
Drug Resistant ◽  
Multiple Drug Resistant

Infections, that are resistant to the various antibiotics, have increased and become a major concern in the field of drug discovery. This has initiated the need to improve the quality of the existing drugs or find an innovative set of strategies to overcome this issue. In the hope of treating multiple-drug resistant infections, the concept of using natural products to form nanoparticles that could resolve the problem has been introduced. This review talks about the myriad ways of synthesis of silver nanoparticles from natural products which helps in the treatment of multiple diseases.

scholarly journals Biomedical Potentialities of Silver Nanoparticles for Clinical Multiple Drug-Resistant Acinetobacter baumannii

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Minghui Chen ◽  
Xiaoxu Yu ◽  
Qianyu Huo ◽  
Qin Yuan ◽  
Xue Li ◽  
...  
Keyword(s):  
Silver Nanoparticles ◽  
Clinical Problem ◽  
Multidrug Resistant ◽  
Multiple Drug ◽  
High Morbidity ◽  
Dependent Manner ◽  
Drug Resistant ◽  
Concentration Dependent Manner ◽  
Multiple Drug Resistant ◽  
New Strategy

Multidrug-resistant A. baumannii is increasingly recognized as a significant problem in hospitals and causes high morbidity and mortality. Here, we studied the antibacterial effects of AgNPs on clinically isolated multiple drug-resistant A. baumannii, and search for the potential antibacterial mechanism. Based on the results from the colony-forming unit (CFU) method, flow cytometry (FC), and a BrdU ELISA, we conclude that AgNPs can simultaneously induce apoptosis and inhibit new DNA synthesis in bacteria in a concentration-dependent manner. This study presents the first discussion of an antibacterial effect by AgNPs in clinically isolated, multidrug-resistant A. Baumannii and provides a new strategy for the use of silver nanoparticles in the multidrug-resistant A. Baumannii clinical problem.

scholarly journals Two Decades of TB Drug Discovery Efforts—What Have We Learned?

2020 ◽  
Vol 10 (16) ◽  
pp. 5704 ◽  
Author(s):  
Balachandra Bandodkar ◽  
Radha Krishan Shandil ◽  
Jagadeesh Bhat ◽  
Tanjore S. Balganesh
Keyword(s):  
Drug Discovery ◽  
Multiple Drug ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Systematic Analysis ◽  
Resistant Tuberculosis ◽  
Extensively Drug Resistant ◽  
Limited Success ◽  
Multiple Drug Resistant ◽  
Key Drivers

After several years of limited success, an effective regimen for the treatment of both drug-sensitive and multiple-drug-resistant tuberculosis is in place. However, this success is still incomplete, as we need several more novel combinations to treat extensively drug-resistant tuberculosis, as well newer emerging resistance. Additionally, the goal of a shortened therapy continues to evade us. A systematic analysis of the tuberculosis drug discovery approaches employed over the last two decades shows that the lead identification path has been largely influenced by the improved understanding of the biology of the pathogen Mycobacterium tuberculosis. Interestingly, the drug discovery efforts can be grouped into a few defined approaches that predominated over a period of time. This review delineates the key drivers during each of these periods. While doing so, the author’s experiences at AstraZeneca R&D, Bangalore, India, on the discovery of new antimycobacterial candidate drugs are used to exemplify the concept. Finally, the review also discusses the value of validated targets, promiscuous targets, the current anti-TB pipeline, the gaps in it, and the possible way forward.

scholarly journals trans-Translation inhibitors bind to a novel site on the ribosome and clear Neisseria gonorrhoeae in vivo

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Zachary D. Aron ◽  
Atousa Mehrani ◽  
Eric D. Hoffer ◽  
Kristie L. Connolly ◽  
Pooja Srinivas ◽  
...  
Keyword(s):  
Oral Dose ◽  
Neisseria Gonorrhoeae ◽  
Multiple Drug ◽  
Specific Inhibition ◽  
Drug Resistant ◽  
Peptidyl Transfer ◽  
Bacterial Ribosome ◽  
Multiple Drug Resistant ◽  
Unique Site

AbstractBacterial ribosome rescue pathways that remove ribosomes stalled on mRNAs during translation have been proposed as novel antibiotic targets because they are essential in bacteria and are not conserved in humans. We previously reported the discovery of a family of acylaminooxadiazoles that selectively inhibit trans-translation, the main ribosome rescue pathway in bacteria. Here, we report optimization of the pharmacokinetic and antibiotic properties of the acylaminooxadiazoles, producing MBX-4132, which clears multiple-drug resistant Neisseria gonorrhoeae infection in mice after a single oral dose. Single particle cryogenic-EM studies of non-stop ribosomes show that acylaminooxadiazoles bind to a unique site near the peptidyl-transfer center and significantly alter the conformation of ribosomal protein bL27, suggesting a novel mechanism for specific inhibition of trans-translation by these molecules. These results show that trans-translation is a viable therapeutic target and reveal a new conformation within the bacterial ribosome that may be critical for ribosome rescue pathways.

Sign in / Sign up

Export Citation Format

Share Document